HORMONAL ANTINEOPLASTIC AGENTS
\hɔːmˈə͡ʊnə͡l ˌantɪnˌiːə͡ʊplˈastɪk ˈe͡ɪd͡ʒənts], \hɔːmˈəʊnəl ˌantɪnˌiːəʊplˈastɪk ˈeɪdʒənts], \h_ɔː_m_ˈəʊ_n_əl ˌa_n_t_ɪ_n_ˌiː__əʊ_p_l_ˈa_s_t_ɪ_k ˈeɪ_dʒ_ə_n_t_s]\
Sort: Oldest first
-
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
By DataStellar Co., Ltd
Word of the day
Proto Oncogene Proteins c erbB 2
- cell surface protein-tyrosine kinase that is found to be overexpressed in significant number adenocarcinomas. It has extensive homology can heterodimerize EGF EPIDERMAL GROWTH FACTOR), 3 receptor (RECEPTOR, 3) and the 4 receptor. Activation of erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB family members. EC 2.7.11.-.